ConductScience.org, home

Paper42423955

Platinum-based chemotherapy in metastatic castration-resistant prostate cancer: a narrative review and dual stratification framework based on HRR genotype and aggressive-variant/neuroendocrine phenotype.

Chen H and 4 others. Int Urol Nephrol, 2026. Cited by 2 papers, by iCite.

Cite this record

ConductScience Library. Platinum-based chemotherapy in metastatic castration-resistant prostate cancer: a narrative review and dual stratification framework based on HRR genotype and aggressive-variant/neuroendocrine phenotype. Papers, record 42423955. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42423955

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Platinum-based chemotherapy in metastatic castration-resistant prostate cancer: a narrative review and dual stratification framework based on HRR genotype and aggressive-variant/neuroendocrine phenotype.
PubMed
Journal
Int Urol Nephrol
PubMed
Year
2026
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
2
iCite
Revised in PubMed
2026-07-09
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Chen HHuan
2Wang YYan
3Ding YYunfei
4Qu MMin
5Gao XXu

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References57

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
126546618Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers.Clin Cancer Res2016https://conductscience.org/library/papers/26546618PubMed
233112397Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations.JAMA Netw Open2020https://conductscience.org/library/papers/33112397PubMed
333904759Distinct Response to Platinum-Based Chemotherapy among Patients with Metastatic Castration-Resistant Prostate Cancer Harboring Alterations in Genes Involved in Homologous Recombination.J Urol2021https://conductscience.org/library/papers/33904759PubMed
433690902Differential treatment outcomes in BRCA1/2-, CDK12-, and ATM-mutated metastatic castration-resistant prostate cancer.Cancer2021https://conductscience.org/library/papers/33690902PubMed
532856010Platinum-Based Chemotherapy in Metastatic Prostate Cancer With DNA Repair Gene Alterations.JCO Precis Oncol2020https://conductscience.org/library/papers/32856010PubMed
631515154Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial.Lancet Oncol2019https://conductscience.org/library/papers/31515154PubMed
737722977
Poly (ADP-ribose) Polymerase Inhibitors Have Comparable Efficacy with Platinum Chemotherapy in Patients with BRCA-positive Metastatic Castration-resistant Prostate Cancer. A Systematic Review and Meta-analysis.
Eur Urol Oncol2024https://conductscience.org/library/papers/37722977PubMed
840413129
Results from a Phase 2 Study of Induction Docetaxel and Carboplatin Followed by Maintenance Rucaparib in the Treatment of Patients with Metastatic Castration-resistant Prostate Cancer with DNA Homologous Recombination Repair Deficiency.
Eur Urol Oncol2026https://conductscience.org/library/papers/40413129PubMed
937193610Outcomes of Second-Line Therapies in Patients With Metastatic de Novo and Treatment-Emergent Neuroendocrine Prostate Cancer: A Multi-Institutional Study.Clin Genitourin Cancer2023https://conductscience.org/library/papers/37193610PubMed
1037648316Second-Line Systemic Therapy for Highly Aggressive Neuroendocrine Prostate Cancer.Anticancer Res2023https://conductscience.org/library/papers/37648316PubMed
1131525487Clinical features of neuroendocrine prostate cancer.Eur J Cancer2019https://conductscience.org/library/papers/31525487PubMed
1230713600Clinical characteristics, treatment outcomes and potential novel therapeutic options for patients with neuroendocrine carcinoma of the prostate.Oncotarget2019https://conductscience.org/library/papers/30713600PubMed
1335347041Treatment Outcomes in Neuroendocrine Prostate Cancer.Anticancer Res2022https://conductscience.org/library/papers/35347041PubMed
1433339136Neuroendocrine and Aggressive-Variant Prostate Cancer.Cancers (Basel)2020https://conductscience.org/library/papers/33339136PubMed
1536200788The Value of Phenotypic Precision Medicine in Prostate Cancer.Oncologist2023https://conductscience.org/library/papers/36200788PubMed
1634948423Combined In Silico, Ex Vivo, and In Vivo Assessment of L-17, a Thiadiazine Derivative with Putative Neuro- and Cardioprotective and Antidepressant Effects.Int J Mol Sci2021https://conductscience.org/library/papers/34948423PubMed
1726724258Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer.Eur Urol2016https://conductscience.org/library/papers/26724258PubMed
1828608931The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer.Cancer2017https://conductscience.org/library/papers/28608931PubMed
1930340782Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency.Eur Urol2019https://conductscience.org/library/papers/30340782PubMed
2038484203
Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis.
J Clin Oncol2024https://conductscience.org/library/papers/38484203PubMed

See all 57 referencesDownload CSV of references

Cited by2

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.

PMIDTitleJournalYearIn PapersSource
42545565Comment on "Deficit accumulation frailty and risk of incident chronic kidney disease: a prospective analysis of the UK Biobank and CHARLS cohorts".Int Urol Nephrol2026https://conductscience.org/library/papers/42545565PubMed
42479376Frailty and chronic kidney disease: beyond risk prediction toward frailty-informed CKD classification.Int Urol Nephrol2026https://conductscience.org/library/papers/42479376PubMed

Download CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ATM472PubTator's text mininghttps://conductscience.org/library/genes/472NCBI Gene
BRCA2675PubTator's text mininghttps://conductscience.org/library/genes/675NCBI Gene
CDK1251755PubTator's text mininghttps://conductscience.org/library/genes/51755NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42423955

GET https://conductscience.org/api/papers/v1/42423955/references?page=2